肿瘤负荷对晚期肺癌预后的影响及 预测模型的构建
The Impact of Tumor Burden on the Prognosis of Advanced Lung Cancer and the Construction of a Predictive Model
DOI: 10.12677/acm.2026.1641536, PDF,    科研立项经费支持
作者: 栾尚扬, 黄彤彤, 田家伟, 傅乙轩, 孙慧昕:青岛大学青岛医学院,山东 青岛;辛 颖:青岛大学附属医院内分泌与代谢性疾病科,山东 青岛;杜忠彩:青岛大学附属医院感染性疾病科,山东 青岛;徐 涛*:青岛大学附属医院呼吸与危重症医学科,山东 青岛
关键词: 肺癌肿瘤负荷无进展生存期Lung Cancer Tumor Burden Progression-Free Survival Period (PFS)
摘要: 目的:探究肿瘤负荷等多因素对晚期肺癌患者无进展生存期(PFS)的影响及预测模型的构建。方法:回顾性分析了243例治疗后进展的晚期肺癌患者,根据肿瘤负荷分为3组。收集临床特征等资料,采用Kaplan-Meier法比较各组PFS,并通过Cox回归分析疾病进展的影响因素,构建肺癌预后的多因素Cox预测模型。结果:Kaplan-Meier曲线结果显示,肿瘤负荷越高,PFS越低。多因素Cox分析结果显示,男性患者、肾上腺转移瘤、肝脏转移瘤、低QoL评分为短PFS的独立危险因素。基于此构建的多因素Cox预测模型,其预测1年、2年及3年肿瘤进展的AUC值分别为0.681、0.705和0.827。结论:肿瘤负荷越高,晚期肺癌患者PFS越低,男性、肾上腺转移、肝转移及低生活质量是晚期肺癌快速进展的独立危险因素,据此构建的Cox预测模型准确性较好。
Abstract: Objective: To investigate the influence of multiple factors such as tumor burden on the progression-free survival (PFS) of patients with advanced lung cancer and to construct a predictive model. Methods: A retrospective analysis was conducted on 243 patients with advanced lung cancer who experienced disease progression after treatment. These patients were divided into three groups based on tumor burden. Clinical characteristics and other data were collected. The Kaplan-Meier method was used to compare the PFS of each group, and Cox regression analysis was employed to identify the influencing factors of disease progression. A multivariate Cox prediction model for lung cancer prognosis was constructed. Results: The Kaplan-Meier curve results indicated that the higher the tumor burden, the lower the PFS. The multivariate Cox analysis results showed that male patients, adrenal metastases, liver metastases, and low QoL scores were independent risk factors for short PFS. Based on this, the constructed multivariate Cox prediction model had AUC values of 0.681, 0.705, and 0.827 for predicting tumor progression at 1 year, 2 years, and 3 years, respectively. Conclusion: The higher the tumor burden, the lower the PFS for patients with advanced lung cancer. Male gender, adrenal metastasis, liver metastasis, and low quality of life are independent risk factors for the rapid progression of advanced lung cancer. The constructed Cox prediction model has good accuracy based on these factors.
文章引用:栾尚扬, 辛颖, 杜忠彩, 黄彤彤, 田家伟, 傅乙轩, 孙慧昕, 徐涛. 肿瘤负荷对晚期肺癌预后的影响及 预测模型的构建[J]. 临床医学进展, 2026, 16(4): 2816-2827. https://doi.org/10.12677/acm.2026.1641536

参考文献

[1] Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., et al. (2018) Global Surveillance of Trends in Cancer Survival 2000-14 (CONCORD-3): Analysis of Individual Records for 37 513 025 Patients Diagnosed with One of 18 Cancers from 322 Population-Based Registries in 71 Countries. The Lancet, 391, 1023-1075. [Google Scholar] [CrossRef] [PubMed]
[2] Janmunee, N., Peerawong, T., Rordlamool, P., Bridthikitti, J., Tangthongkum, M., Kongkamol, C., et al. (2021) Tumor Volume as a Prognostic Factor on the Median Survival in Locally Advanced Oral Cancer Treated with Definitive Chemoradiotherapy. Indian Journal of Cancer, 60, 72-79. [Google Scholar] [CrossRef] [PubMed]
[3] Jardali, G., Lawrance, L., Dawi, L., et al. (2025) Baseline CT-Derived Tumor Burden and Liquid Biopsy as Biomarkers to Predict Survival in Patients with Metastatic Solid Cancer. Diagnostic and Interventional Imaging, 106, 430-437.
[4] Nicolò, E., Tarantino, P., D’Ecclesiis, O., Antonarelli, G., Boscolo Bielo, L., Marra, A., et al. (2023) Baseline Tumor Size as Prognostic Index in Patients with Advanced Solid Tumors Receiving Experimental Targeted Agents. The Oncologist, 29, 75-83. [Google Scholar] [CrossRef] [PubMed]
[5] Sasaki, K., Morioka, D., Conci, S., Margonis, G.A., Sawada, Y., Ruzzenente, A., et al. (2018) The Tumor Burden Score: A New “Metro-Ticket” Prognostic Tool for Colorectal Liver Metastases Based on Tumor Size and Number of Tumors. Annals of Surgery, 267, 132-141. [Google Scholar] [CrossRef] [PubMed]
[6] Ho, S., Liu, P., Hsu, C., Huang, Y., Liao, J., Su, C., et al. (2022) A New Tumor Burden Score and Albumin-Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma. Cancers, 14, Article 649. [Google Scholar] [CrossRef] [PubMed]
[7] Iacovelli, R., Lanoy, E., Albiges, L. and Escudier, B. (2012) Tumour Burden Is an Independent Prognostic Factor in Metastatic Renal Cell Carcinoma. BJU International, 110, 1747-1753. [Google Scholar] [CrossRef] [PubMed]
[8] Gerber, D.E., Dahlberg, S.E., Sandler, A.B., Ahn, D.H., Schiller, J.H., Brahmer, J.R., et al. (2013) Baseline Tumour Measurements Predict Survival in Advanced Non-Small Cell Lung Cancer. British Journal of Cancer, 109, 1476-1481. [Google Scholar] [CrossRef] [PubMed]
[9] Wei, X., Xu, J., Wang, D., Chen, D., Ren, C., Li, J., et al. (2021) Baseline Lesion Number as an Efficacy Predictive and Independent Prognostic Factor and Its Joint Utility with TMB for PD-1 Inhibitor Treatment in Advanced Gastric Cancer. Therapeutic Advances in Medical Oncology, 13, 1-14.
[10] Li, J., Zhu, H., Sun, L., Xu, W. and Wang, X. (2019) Prognostic Value of Site-Specific Metastases in Lung Cancer: A Population Based Study. Journal of Cancer, 10, 3079-3086. [Google Scholar] [CrossRef] [PubMed]
[11] Riihimäki, M., Hemminki, A., Fallah, M., Thomsen, H., Sundquist, K., Sundquist, J., et al. (2014) Metastatic Sites and Survival in Lung Cancer. Lung Cancer, 86, 78-84. [Google Scholar] [CrossRef] [PubMed]
[12] Ashour Badawy, A., Khedr, G., Omar, A., et al. (2018) Site of Metastases as Prognostic Factors in Unselected Population of Stage IV Non-Small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention, 19, 1907-1910.
[13] Lenci, E., Marcantognini, G., Cognigni, V., Lupi, A., Rinaldi, S., Cantini, L., et al. (2021) Tumor Burden as Possible Biomarker of Outcome in Advanced NSCLC Patients Treated with Immunotherapy: A Single Center, Retrospective, Real-World Analysis. Exploration of Targeted Anti-Tumor Therapy, 2, 227-239. [Google Scholar] [CrossRef] [PubMed]
[14] Miyawaki, T., Kenmotsu, H., Mori, K., Miyawaki, E., Mamesaya, N., Kawamura, T., et al. (2020) Association between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 21, e405-e414. [Google Scholar] [CrossRef] [PubMed]
[15] Higuera Gomez, O., Moreno Paul, A., Ortega Granados, A.L., Ros Martinez, S., Perez Parente, D., Ruiz-Gracia, P., et al. (2021) “High Tumor Burden” in Metastatic Non-Small Cell Lung Cancer: Defining the Concept. Cancer Management and Research, 13, 4665-4670. [Google Scholar] [CrossRef] [PubMed]
[16] Yu, X.Q., Yap, M.L., Cheng, E.S., Ngo, P.J., Vaneckova, P., Karikios, D., et al. (2022) Evaluating Prognostic Factors for Sex Differences in Lung Cancer Survival: Findings from a Large Australian Cohort. Journal of Thoracic Oncology, 17, 688-699. [Google Scholar] [CrossRef] [PubMed]
[17] Metzenmacher, M., Griesinger, F., Hummel, H., Elender, C., Schäfer, H., de Wit, M., et al. (2023) Prognostic Factors in Nonsmall Cell Lung Cancer: Insights from the German CRISP Registry. European Respiratory Journal, 61, Article 2201336. [Google Scholar] [CrossRef] [PubMed]
[18] Polański, J., Chabowski, M., Świątoniowska-Lonc, N., Dudek, K., Jankowska-Polańska, B., Zabierowski, J., et al. (2021) Relationship between Nutritional Status and Clinical Outcome in Patients Treated for Lung Cancer. Nutrients, 13, Article 3332. [Google Scholar] [CrossRef] [PubMed]